Scientists at McGill University and the Rosalind and Morris Goodman Cancer Institute have developed a new way to deliver cancer immunotherapy that caused fewer side effects compared to standard treatment in a preclinical study. The work is published in the journal Proceedings of the National Academy of Sciences.
The experimental approach is designed to treat cancer that has spread to the lymph nodes, a difficult-to-treat stage of the disease. Today, most immunotherapies are delivered by intravenous (IV) infusion and circulate throughout the body. This can trigger immune responses in healthy tissues, leading to serious side effects.
“Some immunotherapies cause such severe side effects that clinicians are forced to lower the dose, making treatment less effective,” said senior author Guojun Chen, Assistant Professor in McGill’s Department of Biomedical Engineering and member of the Goodman Cancer Institute. “Our approach could allow for higher, more effective doses while limiting toxicity, which is a major goal in cancer treatment.”









